文献速递骨质疏松与代谢性骨病创伤骨科

GLP-1受体激动剂与骨折风险的丹麦全国巢式病例对照研究

The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study.
PubMed 文献 · Osteoporos Int · 2026-03-18

该研究基于丹麦全国数据,纳入2017—2021年30—90岁骨折者337,648例,并按性别和出生年1:2匹配无骨折对照675,296例。未调整分析中两组GLP-1受体激动剂使用无差异,调整相关危险因素后骨折组使用更少,提示该药可能降低骨折风险。

核心结论

  • 调整相关危险因素后,GLP-1受体激动剂使用与任何骨折及主要骨质疏松性骨折风险降低相关,提示其可能对骨健康具有保护作用。

研究设计与样本

  • 丹麦全国巢式病例对照研究,纳入2017—2021年30—90岁骨折者337,648例,按性别和出生年1:2匹配无骨折对照675,296例,采用条件logistic回归分析。

临床怎么用

  • 对于使用GLP-1受体激动剂的患者,该研究结果提示其骨折风险可能不升高甚至降低,但需结合个体情况评估骨健康。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: To examine whether GLP1-RA is associated with increased fracture risk, we compared 337,648 people with fractures to 675,296 people without fractures. Our adjusted analysis found that people with fractures tended to use GLP1-RA less often than people without fractures. This suggests that GLP1-RA may reduce fracture risk. BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists were introduced as a treatment for type 2 diabetes mellitus with weight loss as a beneficial side effect. Since then, the medications have been approved as weight-loss medication. However, rapid and substantial weight loss can lead to bone loss and increased fracture risk. METHODS: We identified persons aged 30-90 years with a fracture between 2017 and 2021 and matched them 1:2 with fracture-free controls by sex and year of birth. Conditional logistic regression models were used to estimate odds ratios (ORs) for any fracture and major osteoporotic fracture (MOF) associated with GLP-1 receptor agonist use. Analyses were adjusted for relevant risk factors. RESULTS: A total of 337,648 fracture cases and 675,296 fracture-free controls were included. In the unadjusted analyses, GLP-1 receptor agonist use did not differ between cases and controls (any fracture OR [confidence intervals (CI)], 1.00 [0.97-1.04]; MOF OR [CI], 0.96 [0.90-1.02]). In the adjusted analyses, GLP-1 receptor agonists were used less frequently in the group that sustained any fracture (OR [CI], 0.94 [0.90-0.97]) or MOF (OR [CI], 0.88 [0.83-0.94]) compared to the controls. CONCLUSION: GLP-1 receptor agonists may reduce fracture risk, suggesting a potential protective effect on bone health.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kvist AV, Andersen SS, Vestergaard P, et al. The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study. Osteoporos Int. 2026. PMID: 41851446. doi:10.1007/s00198-026-07950-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。